132 related articles for article (PubMed ID: 9424007)
1. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study.
Saunders MI; Hoskin PJ; Pigott K; Powell ME; Goodchild K; Dische S; Denekamp J; Stratford MR; Dennis MF; Rojas AM
Radiother Oncol; 1997 Nov; 45(2):159-66. PubMed ID: 9424007
[TBL] [Abstract][Full Text] [Related]
2. ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC.
Bernier J; Denekamp J; Rojas A; Trovò M; Horiot JC; Hamers H; Antognoni P; Dahl O; Richaud P; Kaanders J; van Glabbeke M; Piérart M
Radiother Oncol; 1999 Aug; 52(2):149-56. PubMed ID: 10577700
[TBL] [Abstract][Full Text] [Related]
3. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON).
Zackrisson B; Franzén L; Henriksson R; Littbrand B; Stratford M; Dennis M; Rojas AM; Denekamp J
Acta Oncol; 1994; 33(4):377-81. PubMed ID: 8018369
[TBL] [Abstract][Full Text] [Related]
4. ARCON: experience in 215 patients with advanced head-and-neck cancer.
Kaanders JH; Pop LA; Marres HA; Bruaset I; van den Hoogen FJ; Merkx MA; van der Kogel AJ
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):769-78. PubMed ID: 11849800
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity.
Kaanders JH; Pop LA; Marres HA; van der Maazen RW; van der Kogel AJ; van Daal WA
Radiother Oncol; 1995 Dec; 37(3):190-8. PubMed ID: 8746587
[TBL] [Abstract][Full Text] [Related]
6. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933.
Miralbell R; Mornex F; Greiner R; Bolla M; Storme G; Hulshof M; Bernier J; Denekamp J; Rojas AM; Pierart M; van Glabbeke M; Mirimanoff RO
J Clin Oncol; 1999 Oct; 17(10):3143-9. PubMed ID: 10506611
[TBL] [Abstract][Full Text] [Related]
7. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).
Bernier J; Denekamp J; Rojas A; Minatel E; Horiot J; Hamers H; Antognoni P; Dahl O; Richaud P; van Glabbeke M; Piérart M
Radiother Oncol; 2000 May; 55(2):111-9. PubMed ID: 10799722
[TBL] [Abstract][Full Text] [Related]
8. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
Kaanders JH; Pop LA; Marres HA; Liefers J; van den Hoogen FJ; van Daal WA; van der Kogel AJ
Radiother Oncol; 1998 Aug; 48(2):115-22. PubMed ID: 9783882
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Bernier J; Stratford MR; Denekamp J; Dennis MF; Bieri S; Hagen F; Kocagöncü O; Bolla M; Rojas A
Radiother Oncol; 1998 Aug; 48(2):123-33. PubMed ID: 9783883
[TBL] [Abstract][Full Text] [Related]
10. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
Janssens GO; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Pop LA; Kaanders JH
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):532-8. PubMed ID: 21300447
[TBL] [Abstract][Full Text] [Related]
11. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Marres HA; de Bree R; van der Kogel AJ; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
J Clin Oncol; 2012 May; 30(15):1777-83. PubMed ID: 22508814
[TBL] [Abstract][Full Text] [Related]
12. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study.
Hoskin P; Rojas A; Saunders M
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1425-31. PubMed ID: 19036531
[TBL] [Abstract][Full Text] [Related]
13. ARCON: a novel biology-based approach in radiotherapy.
Kaanders JH; Bussink J; van der Kogel AJ
Lancet Oncol; 2002 Dec; 3(12):728-37. PubMed ID: 12473514
[TBL] [Abstract][Full Text] [Related]
14. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
Hoogsteen IJ; Pop LA; Marres HA; Merkx MA; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):83-9. PubMed ID: 16213107
[TBL] [Abstract][Full Text] [Related]
15. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
Hoskin PJ; Rojas AM; Phillips H; Saunders MI
Cancer; 2005 Jun; 103(11):2287-97. PubMed ID: 15834926
[TBL] [Abstract][Full Text] [Related]
16. Carbogen breathing combined with radical radiotherapy in advanced head and neck cancer patients with severe co-morbidities.
Vees H; Allal AS
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):493-6. PubMed ID: 16909974
[TBL] [Abstract][Full Text] [Related]
17. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen.
Horsman MR; Overgaard J
Radiother Oncol; 2004 Mar; 70(3):301-9. PubMed ID: 15064017
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x-ray schedules.
Rojas A; Vojnovic B; Johns H; Joiner MC; Martindale C; Fowler JF; Denekamp J
Radiother Oncol; 1996 Apr; 39(1):53-64. PubMed ID: 8735494
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.
Bussink J; Stratford MR; van der Kogel AJ; Folkes LK; Kaanders JH
Radiother Oncol; 2002 Jun; 63(3):285-91. PubMed ID: 12142092
[TBL] [Abstract][Full Text] [Related]
20. Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial.
Janssens GO; van Bockel LW; Doornaert PA; Bijl HP; van den Ende P; de Jong MA; van den Broek GB; Verbist BM; Terhaard CH; Span PN; Kaanders JH
Eur J Cancer; 2014 Apr; 50(6):1112-9. PubMed ID: 24424106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]